As of January 22, 2025, Belite Bio (BLTE) has a market cap of $1.82 billion USD. According to our data, Belite Bio is ranked No.4282 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $1.82 B |
-6.50%
|
Dec 31, 2024 | $1.95 B |
37.92%
|
Dec 29, 2023 | $1.41 B |
51.77%
|
Dec 30, 2022 | $0.93 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Apellis Pharmaceuticals
APLS
|
$3.77 B |
0.000 M
|
USA
|
Kodiak Sciences
KOD
|
$0.41 B |
0.000 M
|
USA
|
Adverum Biotechnologies
ADVM
|
$91.74 M |
0.000 M
|
USA
|
REGENXBIO
RGNX
|
$0.37 B |
0.000 M
|
USA
|
Clearside Biomedical
CLSD
|
$71.64 M |
0.000 M
|
USA
|
ProQR
PRQR
|
$0.23 B |
0.000 M
|
Netherlands
|
MeiraGTx
MGTX
|
$0.47 B |
-0.000 M
|
USA
|
Editas Medicine
EDIT
|
$0.10 B |
-0.000 M
|
USA
|
Editas Medicine
EDIT
|
$0.10 B |
-0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.82 B |
6.828 M
|
Switzerland
|
Intellia Therapeutics
NTLA
|
$1.03 B |
0.000 M
|
USA
|
Beam Therapeutics
BEAM
|
$2.00 B |
-0.030 B
|
USA
|
Editas Medicine
EDIT
|
$0.10 B |
-0.000 M
|
USA
|
Market Cap | = | BLTE Stock Price | * | BLTE Shares Outstanding |
= | $59.00 | * | 30.88 M | |
= | $1.82 B |